121 related articles for article (PubMed ID: 7620216)
1. Novel N-oxides as bioreductive drugs.
Naylor MA
Oncol Res; 1994; 6(10-11):483-91. PubMed ID: 7620216
[TBL] [Abstract][Full Text] [Related]
2. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
[TBL] [Abstract][Full Text] [Related]
3. Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalines.
Naylor MA; Stephens MA; Nolan J; Sutton B; Tocher JH; Fielden EM; Adams GE; Stratford IJ
Anticancer Drug Des; 1993 Dec; 8(6):439-61. PubMed ID: 8286012
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues.
Solano B; Junnotula V; Marín A; Villar R; Burguete A; Vicente E; Pérez-Silanes S; Aldana I; Monge A; Dutta S; Sarkar U; Gates KS
J Med Chem; 2007 Nov; 50(22):5485-92. PubMed ID: 17910426
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents.
Nguyen CH; Fan E; Riou JF; Bissery MC; Vrignaud P; Lavelle F; Bisagni E
Anticancer Drug Des; 1995 Jun; 10(4):277-97. PubMed ID: 7786395
[TBL] [Abstract][Full Text] [Related]
6. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
Deleuze-Masquefa C; Moarbess G; Khier S; David N; Gayraud-Paniagua S; Bressolle F; Pinguet F; Bonnet PA
Eur J Med Chem; 2009 Sep; 44(9):3406-11. PubMed ID: 19278757
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro antitumor activity of new quinoxaline derivatives.
Corona P; Carta A; Loriga M; Vitale G; Paglietti G
Eur J Med Chem; 2009 Apr; 44(4):1579-91. PubMed ID: 18774202
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and cytotoxicity of 2-methyl-4, 9-dihydro-1-substituted-1H-imidazo[4,5-g]quinoxaline-4,9-diones and 2,3-disubstituted-5,10-pyrazino[2,3-g]quinoxalinediones.
Yoo HW; Suh ME; Park SW
J Med Chem; 1998 Nov; 41(24):4716-22. PubMed ID: 9822542
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs.
Siim BG; Atwell GJ; Anderson RF; Wardman P; Pullen SM; Wilson WR; Denny WA
J Med Chem; 1997 Apr; 40(9):1381-90. PubMed ID: 9135035
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives.
Moarbess G; Deleuze-Masquefa C; Bonnard V; Gayraud-Paniagua S; Vidal JR; Bressolle F; Pinguet F; Bonnet PA
Bioorg Med Chem; 2008 Jul; 16(13):6601-10. PubMed ID: 18513976
[TBL] [Abstract][Full Text] [Related]
12. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
Lee HH; Wilson WR; Denny WA
Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.
Urquiola C; Vieites M; Torre MH; Cabrera M; Lavaggi ML; Cerecetto H; González M; Cerain AL; Monge A; Smircich P; Garat B; Gambino D
Bioorg Med Chem; 2009 Feb; 17(4):1623-9. PubMed ID: 19162490
[TBL] [Abstract][Full Text] [Related]
15. Quinoxaline chemistry. Part 5. 2-(R)-benzylaminoquinoxalines as nonclassical antifolate agents. Synthesis and evaluation of in vitro anticancer activity.
Loriga M; Fiore M; Sanna P; Paglietti G
Farmaco; 1996; 51(8-9):559-68. PubMed ID: 8930109
[TBL] [Abstract][Full Text] [Related]
16. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.
Henderson ND; Plumb JA; Robins DJ; Workman P
Anticancer Drug Des; 1996 Sep; 11(6):421-38. PubMed ID: 8836108
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivatives.
Zarranz B; Jaso A; Aldana I; Monge A
Bioorg Med Chem; 2004 Jul; 12(13):3711-21. PubMed ID: 15186857
[TBL] [Abstract][Full Text] [Related]
19. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs.
Patterson LH; Craven MR; Fisher GR; Teesdale-Spittle P
Oncol Res; 1994; 6(10-11):533-8. PubMed ID: 7620222
[TBL] [Abstract][Full Text] [Related]
20. A new efficient route for the formation of quinoxaline N-oxides and N,N'-dioxides using HOF.CH3CN.
Carmeli M; Rozen S
J Org Chem; 2006 Jul; 71(15):5761-5. PubMed ID: 16839160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
